Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 5/20 | 0.52 |
| ▸ | MAP4K1 | Q92918 | 5/20 | 0.52 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
| ▸ | IRAK4 | Q9NWZ3 | 12/20 | 0.47 |
| ▸ | PIM1 | P11309 | 3/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18889882 | 0.93 | IRAK4 (0.52) | NTRK1MAP4K1PRKAA1FLT3IRAK4 | |
| SCHEMBL17382890 | 0.93 | IRAK4 (0.52) | NTRK1MAP4K1PRKAA1FLT3IRAK4 | |
| SCHEMBL17373840 | 0.93 | NTRK1 (0.58) | NTRK1MAP4K1PRKAA1FLT3IRAK4 | |
| SCHEMBL30659518 | 0.93 | NTRK1 (0.58) | NTRK1MAP4K1PRKAA1FLT3IRAK4 | |
| SCHEMBL17373838 | 0.93 | NTRK1 (0.58) | NTRK1MAP4K1PRKAA1FLT3IRAK4 | |
| SCHEMBL16899027 | 0.90 | IRAK4 (0.52) | NTRK1MAP4K1PRKAA1FLT3IRAK4 | |
| SCHEMBL16906710 | 0.90 | IRAK4 (0.52) | NTRK1MAP4K1PRKAA1FLT3IRAK4 | |
| SCHEMBL16906696 | 0.90 | IRAK4 (0.52) | NTRK1MAP4K1PRKAA1FLT3IRAK4 | |
| Trifluoroacetic Acid SCHEMBL16899011 | 0.85 | IRAK4 (0.48) | NTRK1MAP4K1PRKAA1FLT3IRAK4 | |
| Trifluoroacetic Acid SCHEMBL16899010 | 0.85 | IRAK4 (0.48) | NTRK1MAP4K1PRKAA1FLT3IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11419875-B2 | Compounds and compositions for treating hematological disorders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-08-23 | — | — | US | disclosed |
| US-20210290628-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-09-23 | — | — | US | disclosed |
| US-20200345704-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | CURIS, INC. | 2020-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200345704-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | IRAK4, IRAK2, JAK2 | NTRK1 3731/4885MAP4K1 472/4885PRKAA1 1013/4885 |
| US-20210290628-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | IRAK4, FLT3, IRAK3 | NTRK1 2644/4885MAP4K1 218/4885PRKAA1 765/4885 |
| US-11419875-B2 | Compounds and compositions for treating hematological disorders | IRAK4, FLT3, IRAK3 | NTRK1 2644/4885MAP4K1 218/4885PRKAA1 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.